Takeda Pharmaceutical Li... (TAK)
14.78
-0.27 (-1.79%)
At close: Mar 31, 2025, 10:28 AM
Takeda Pharmaceutical Cash Flow Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 | FY09 | FY08 | FY07 | FY06 | FY05 | FY04 | FY03 | FY02 | FY01 | FY00 | FY99 |
| Net Income | 144.07B | 317.04B | 230.17B | 376.17B | 44.29B | 109.01B | 186.71B | 115.51B | 83.48B | -143.03B | 109.56B | 129.71B | 252.48B | 371.57B | 415.83B | 398.55B | 576.84B | 625.38B | 517.96B | 441.1B | 446.14B | 431.9B | 235.66B | 263.08B | 119.63B |
| Depreciation & Amortization | 728B | 664.4B | 583.15B | 559.67B | 583.65B | 272.45B | 182.13B | 222.79B | 197.38B | 260.95B | 215.74B | 201.11B | 150.19B | 106.72B | 114.83B | 118.08B | 31.69B | 28.82B | 28.73B | 31.23B | 28.08B | 29.96B | 28.43B | 33.6B | 33.36B |
| Stock-Based Compensation | 70.87B | 60.67B | 43.37B | 37.66B | 29.12B | 20.08B | 18.61B | 17.41B | 14.71B | 20.35B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Working Capital | -145.47B | 31.9B | -58.09B | 49.1B | 21.94B | 47.06B | -6.53B | 20.55B | -290.65B | 316.47B | 44.63B | 27.25B | 15.41B | -8.6B | 21.52B | -25.92B | 5.8B | -28.81B | -4.37B | -25.21B | -12.29B | 11.89B | 5.86B | -33.3B | -6.93B |
| Other Non-Cash Items | 120.81B | -97.74B | 95.4B | -228.42B | 23.06B | -134.89B | -53.49B | 25.49B | 22.1B | -80.02B | 44.64B | -35.43B | -130.83B | -142.2B | -163.63B | -153.44B | -307.33B | -409.06B | -163.1B | -148.18B | -146.84B | -205.13B | -27.75B | -48.98B | 11.39B |
| Deferred Income Tax | -91.41B | 58.05B | 72.41B | -9.94B | -105.04B | -14.12B | 30.5B | 27.83B | 37.06B | -2.4B | 49.29B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Change in Working Capital | -256B | -25.26B | 98.61B | 275.78B | 94.67B | 75.95B | 13.4B | 29.68B | -267.21B | 262.33B | -57.12B | 12.33B | 64.72B | -9.16B | 14.15B | -36.92B | -8.71B | -35.86B | -10.01B | -28.61B | -16.26B | 6.72B | 4.25B | -35.04B | -5.41B |
| Operating Cash Flow | 716.34B | 977.16B | 1,123.1B | 1,010.9B | 669.75B | 328.48B | 377.85B | 261.36B | 25.49B | 182.52B | 148.34B | 307.71B | 336.57B | 326.94B | 381.17B | 326.27B | 292.5B | 209.28B | 373.57B | 295.54B | 311.12B | 263.45B | 240.59B | 212.66B | 158.96B |
| Capital Expenditures | -480.73B | -633.69B | -186.04B | -236.47B | -217.71B | -134.11B | -128.26B | -112.03B | -84.86B | -108.72B | -78.52B | -95.76B | -61.9B | -124.17B | -86.96B | -39.46B | -32.62B | -29.15B | -32.09B | -53.67B | -54.16B | -33.48B | -37.52B | -26.94B | -35.42B |
| Acquisitions | -4.74B | 7.96B | -21.48B | 530.39B | 456.66B | -2,873.6B | 56.75B | -524.74B | -7.05B | -20.43B | -3.34B | -80.82B | -1,040B | 690M | 753M | 559M | -1.76B | 15.08B | 10.77B | -29.09B | 3.09B | 60.41B | 58.91B | 16.54B | 3.02B |
| Purchase of Investments | -40.07B | -10.15B | -8.34B | -12.6B | -7.55B | -17.1B | -88.66B | -82.11B | -40.02B | -3.57B | -141.69B | -1.98B | -572M | -4.05B | -23.93B | -892.67B | -253.09B | -331.02B | -469.86B | -391.29B | -273.95B | -180.23B | -38.95B | -207.1B | -1.02B |
| Sales Maturities Of Investments | 8.02B | 22.25B | 16.92B | 74.6B | 49.4B | 65.03B | 40.74B | 75.27B | 56.45B | 165.36B | 52.27B | 60.28B | 489M | 24.38B | 13.21B | 142.12B | 365.98B | 516.98B | 497.26B | 395.87B | 165.84B | 265.08B | 232.12B | 198.84B | 164.35B |
| Other Investing Acitivies | -251.66B | 6.53B | 808M | 37.6B | 11.32B | 124.03B | 26.08B | -12.09B | 4.26B | 58.71B | 12.67B | 6.91B | 8.04B | 3.89B | -20.59B | 22.2B | 23.23B | -55.49B | 493M | 5.88B | 19.86B | 28.37B | -89.32B | -39.58B | -182.6B |
| Investing Cash Flow | -463.86B | -607.1B | -198.13B | 393.53B | 292.12B | -2,835.7B | -93.34B | -655.69B | -71.21B | 91.35B | -158.61B | -111.38B | -1,094B | -99.25B | -117.52B | -767.26B | 101.75B | 116.39B | 6.57B | -72.31B | -139.32B | 140.15B | 125.24B | -58.25B | -51.67B |
| Debt Repayment | 1.51B | -325.07B | -600.48B | -656.06B | -586.09B | 3,161.5B | -153.14B | 471.42B | 45.92B | -119.5B | 248.9B | -4.86B | 539.3B | -663M | -1.14B | -170M | -2.19B | -1.89B | -2.25B | 2.7B | 2.52B | -2.05B | -1.99B | -4.94B | 1.11B |
| Common Stock Repurchased | -2.33B | -26.93B | -77.53B | -2.14B | -3.74B | -1.17B | -18.76B | -23.12B | -22.35B | -17.59B | -37M | -24M | -16M | -50M | -34M | -280.27B | -128.76B | -213.73B | -156M | -166M | n/a | n/a | n/a | n/a | n/a |
| Dividend Paid | -287.19B | -279.42B | -283.67B | -283.36B | -282.58B | -142.95B | -141.89B | -141.69B | -141.54B | -141.64B | -142.13B | -142.12B | -142.01B | -142.06B | -143.55B | -142.45B | -129.17B | -98.76B | -85.53B | -74.96B | -60.87B | -54.44B | -48.54B | -36.61B | -28.01B |
| Other Financial Acitivies | -66.42B | -77.73B | -108.59B | -146.79B | -132.8B | -71.14B | -12.44B | -16.72B | -6.88B | -22.27B | -5.32B | -5.2B | -3.48B | -3.78B | -3.32B | -2.96B | -1.97B | -1.56B | -1.35B | -1.49B | -999M | -2.51B | -2.12B | -363M | -1.01B |
| Financial Cash Flow | -354.42B | -709.15B | -1,070.3B | -1,088.4B | -1,005.2B | 2,946.2B | -326.23B | 289.9B | -124.84B | -301B | 101.44B | -150.56B | 393.79B | -146.54B | -148.05B | -425.84B | -262.08B | -315.94B | -89.29B | -73.91B | -59.34B | -58.99B | -52.66B | -41.91B | -27.91B |
| Net Cash Flow | -75.73B | -316.17B | -116.53B | 328.61B | -65.11B | 407.12B | -46.73B | -131.97B | -203.82B | -10.8B | 120.47B | 91.33B | -418.46B | 20.23B | 94.4B | -855.16B | -34.45B | 21.46B | 361.91B | 188.24B | 53.13B | 324.64B | 336.64B | 119.76B | 77.96B |
| Free Cash Flow | 235.61B | 343.47B | 937.07B | 774.46B | 452.04B | 194.37B | 249.59B | 149.34B | -59.37B | 73.8B | 69.82B | 211.95B | 274.67B | 202.77B | 294.21B | 286.81B | 259.88B | 180.13B | 341.48B | 241.87B | 256.96B | 229.97B | 203.06B | 185.72B | 123.54B |